Shares of Indivior PLC (NASDAQ: INDV) are surging in pre-market trading, up 12.01%, following the company's impressive second-quarter earnings report that significantly exceeded analyst expectations.

The pharmaceutical company, known for its addiction treatment products, reported quarterly earnings of $0.51 per share, more than doubling the analyst consensus estimate of $0.25. This represents a remarkable 104% beat and a 6.25% increase from the $0.48 per share reported in the same period last year. The substantial earnings beat demonstrates Indivior's strong financial performance and effective cost management.

On the revenue front, Indivior also outperformed, reporting quarterly sales of $302 million. This figure surpassed the analyst consensus estimate of $241.67 million by nearly 25%, showcasing robust demand for the company's products. The sales result also represents a modest 1% year-over-year increase from $299 million. The significant revenue beat, coupled with the even more impressive earnings beat, suggests that Indivior has not only grown its top line but has also improved its operational efficiency and profitability.

Investors are clearly encouraged by these results, as reflected in the stock's pre-market surge. The strong financial performance may boost confidence in Indivior's growth strategy and market position in the addiction treatment sector. As the market opens, all eyes will be on INDV to see if this pre-market enthusiasm translates into sustained gains during the regular trading session.